Vesalius Biocapital
Vesalius Biocapital Partners S.à r.l., founded in 2007 and based in Strassen, Luxembourg, is a venture capital and private equity firm focused on investing in life sciences and novel food applications. The firm targets all stages of development, including seed, early, mid, and late-stage ventures, with a particular emphasis on healthcare, pharmaceuticals, therapeutics, medtech, biotechnology, and nanotechnology. Vesalius Biocapital seeks to support companies that develop innovative drugs, medical devices, and diagnostics addressing unmet medical needs, as well as novel nutrition technologies for disease prevention and treatment. The firm primarily invests in Europe, concentrating on the Benelux countries, German-speaking regions, and Scandinavia, typically committing between €1 million and €5 million in each portfolio company, with the possibility of increasing this amount in subsequent rounds. Vesalius Biocapital usually takes minority equity stakes and plays an active role by leading or co-leading investment syndicates and securing board representation in its portfolio companies. With over €150 million under management across two funds, Vesalius has contributed to the development of 20 companies since its inception.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.
Complix NV is a biopharmaceutical company based in Diepenbeek, Belgium, with research facilities in Zwijnaarde, Belgium, and an office in Esch-sur-Alzette, Luxembourg. Founded in 2008, the company specializes in the discovery and development of Alphabodies, a novel class of protein therapeutics designed to target difficult disease sites, particularly in oncology and autoimmune diseases. These Alphabodies demonstrate high affinity for a variety of disease targets and possess unique stability and versatility, enabling non-injectable delivery methods. Complix aims to address challenging intracellular targets, thereby offering patients alternatives to traditional antibodies and small molecules, with the intent of improving treatment outcomes for complex conditions such as cancer, autoimmune disorders, and viral diseases.